Screener
Ionis Pharmaceuticals IONS Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwards.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Deferred Tax Assets: | ||
| Net operating loss carryovers | $$290,851 | 95,851 |
| Tax credits | 361,056 | 310,703 |
| Deferred revenue | 38,830 | 54,063 |
| Stock-based compensation | 67,585 | 82,660 |
| Intangible and capital assets | 76,283 | 93,541 |
| Convertible debt | 1,305 | 9,310 |
| Capitalized research and development expenses | 233,485 | 323,560 |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's net operating loss carryforwards?
- Ionis Pharmaceuticals (IONS) reported net operating loss carryforwards of $361.06M in Q4 2025.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.
Ask your AI about Ionis Pharmaceuticals's net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude